Citations (178)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (26)
Mizuki Yamane, Fumihiko Igarashi, Tsuyoshi Yamauchi & Toshito Nakagawa. (2021) Main contribution of UGT1A1 and CYP2C9 in the metabolism of UR-1102, a novel agent for the treatment of gout. Xenobiotica 51:1, pages 61-71.
Read now
Read now
Laura Hedges, Susan Brown, A. Kenneth MacLeod, Audrey Vardy, Edward Doyle, Gina Song, Marjory Moreau, Miyoung Yoon, Thomas G. Osimitz & Brian G. Lake. (2019) Metabolism of deltamethrin and cis- and trans-permethrin by human expressed cytochrome P450 and carboxylesterase enzymes. Xenobiotica 49:5, pages 521-527.
Read now
Read now
Raghava Choudary Palacharla, Ramakrishna Nirogi, Venkatesham Uthukam, Arunkumar Manoharan, Ranjith Kumar Ponnamaneni & Ilayaraja Kalaikadhiban. (2018) Quantitative in vitro phenotyping and prediction of drug interaction potential of CYP2B6 substrates as victims. Xenobiotica 48:7, pages 663-675.
Read now
Read now
Li Di. (2017) Reaction phenotyping to assess victim drug-drug interaction risks. Expert Opinion on Drug Discovery 12:11, pages 1105-1115.
Read now
Read now
Yannick Parmentier, Corinne Pothier, Audrey Delmas, Fabrice Caradec, Marie-Michèle Trancart, Fabrice Guillet, Belkacem Bouaita, Christophe Chesne, J. Brian Houston & Bernard Walther. (2017) Direct and quantitative evaluation of the human CYP3A4 contribution (fm) to drug clearance using the in vitro SILENSOMES model. Xenobiotica 47:7, pages 562-575.
Read now
Read now
Ken-Ichi Umehara, Markus Zollinger, Elizabeth Kigondu, Marc Witschi, Claire Juif, Felix Huth, Hilmar Schiller, Kelly Chibale & Gian Camenisch. (2016) Esterase phenotyping in human liver in vitro: specificity of carboxylesterase inhibitors. Xenobiotica 46:10, pages 862-867.
Read now
Read now
William Brian, Larry M Tremaine, Million Arefayene, Ruben de Kanter, Raymond Evers, Yingying Guo, James Kalabus, Wen Lin, Cho-Ming Loi & Guangqing Xiao. (2016) Assessment of Drug Metabolism Enzyme and Transporter Pharmacogenetics in Drug Discovery and Early Development: Perspectives of the I-Pwg. Pharmacogenomics 17:6, pages 615-631.
Read now
Read now
Christopher R. Gibson, Ping Lu, Cheri Maciolek, Christen Wudarski, Zoe Barter, Karen Rowland-Yeo, Mark Stroh, Eseng Lai & Deborah A. Nicoll-Griffith. (2013) Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans. Xenobiotica 43:12, pages 1027-1036.
Read now
Read now
Karen Rowland Yeo, Masoud Jamei & Amin Rostami-Hodjegan. (2013) Predicting drug–drug interactions: application of physiologically based pharmacokinetic models under a systems biology approach. Expert Review of Clinical Pharmacology 6:2, pages 143-157.
Read now
Read now
Miyoung Yoon, Jerry L. Campbell, Melvin E. Andersen & Harvey J. Clewell. (2012) Quantitative in vitro to in vivo extrapolation of cell-based toxicity assay results. Critical Reviews in Toxicology 42:8, pages 633-652.
Read now
Read now
Hannah M Jones, Maurice Dickins, Kuresh Youdim, James R Gosset, Neil J Attkins, Tanya L Hay, Ian K Gurrell, Y Raj Logan, Peter J Bungay, Barry C Jones & Iain B Gardner. (2012) Application of PBPK modelling in drug discovery and development at Pfizer. Xenobiotica 42:1, pages 94-106.
Read now
Read now
Helen E. Cubitt, Karen R. Yeo, Eleanor M. Howgate, Amin Rostami-Hodjegan & Zoe E. Barter. (2011) Sources of interindividual variability in IVIVE of clearance: an investigation into the prediction of benzodiazepine clearance using a mechanistic population-based pharmacokinetic model. Xenobiotica 41:8, pages 623-638.
Read now
Read now
Karen Rowland Yeo, Mohsen Aarabi, Masoud Jamei & Amin Rostami-Hodjegan. (2011) Modeling and predicting drug pharmacokinetics in patients with renal impairment. Expert Review of Clinical Pharmacology 4:2, pages 261-274.
Read now
Read now
Hege Christensen, Anette L. Hestad, Espen Molden & Liv Mathiesen. (2011) CYP3A5-mediated metabolism of midazolam in recombinant systems is highly sensitive to NADPH-cytochrome P450 reductase activity. Xenobiotica 41:1, pages 1-5.
Read now
Read now
John O. Miners, Peter I. Mackenzie & Kathleen M. Knights. (2010) The prediction of drug-glucuronidation parameters in humans: UDP-glucuronosyltransferase enzyme-selective substrate and inhibitor probes for reaction phenotyping and in vitro–in vivo extrapolation of drug clearance and drug-drug interaction potential. Drug Metabolism Reviews 42:1, pages 196-208.
Read now
Read now
Thierry Lavé, Kathryn Chapman, Paul Goldsmith & Malcolm Rowland. (2009) Human clearance prediction: shifting the paradigm. Expert Opinion on Drug Metabolism & Toxicology 5:9, pages 1039-1048.
Read now
Read now
C. R. Gibson, A. Bergman, P. Lu, F. Kesisoglou, W. S. Denney & E. Mulrooney. (2009) Prediction of Phase I single-dose pharmacokinetics using recombinant cytochromes P450 and physiologically based modelling. Xenobiotica 39:9, pages 637-648.
Read now
Read now
. (2008) Abstracts from the 10th European Regional ISSX Meeting. Drug Metabolism Reviews 40:sup1, pages 1-172.
Read now
Read now
Stefan S De Buck & Claire E Mackie. (2007) Physiologically based approaches towards the prediction of pharmacokinetics: in vitro–in vivo extrapolation. Expert Opinion on Drug Metabolism & Toxicology 3:6, pages 865-878.
Read now
Read now
P. J. H. Webborn, A. J. Parker, R. L. Denton & R. J. Riley. (2007) – extrapolation of hepatic clearance involving active uptake: Theoretical and experimental aspects. Xenobiotica 37:10-11, pages 1090-1109.
Read now
Read now
T. Lavé, N. Parrott, H. P. Grimm, A. Fleury & M. Reddy. (2007) Challenges and opportunities with modelling and simulation in drug discovery and drug development. Xenobiotica 37:10-11, pages 1295-1310.
Read now
Read now
Hongjian Zhang, Carl D Davis, Michael W Sinz & A David Rodrigues. (2007) Cytochrome P450 reaction-phenotyping: an industrial perspective. Expert Opinion on Drug Metabolism & Toxicology 3:5, pages 667-687.
Read now
Read now
Jan L Wahlstrom, Dan A Rock, J Greg Slatter & Larry C Wienkers. (2006) Advances in predicting CYP-mediated drug interactions in the drug discovery setting. Expert Opinion on Drug Discovery 1:7, pages 677-691.
Read now
Read now
M. R. Shiran, N. J. Proctor, E. M. Howgate, K. Rowland-Yeo, G. T. Tucker & A. Rostami-Hodjegan. (2006) Prediction of metabolic drug clearance in humans: extrapolation allometric scaling. Xenobiotica 36:7, pages 567-580.
Read now
Read now
E. M. Howgate, K. Rowland Yeo, N. J. Proctor, G. T. Tucker & A. Rostami-Hodjegan. (2006) Prediction of in vivo drug clearance from in vitro data. I: Impact of inter-individual variability. Xenobiotica 36:6, pages 473-497.
Read now
Read now
M. G. Soars, K. Grime & R. J. Riley. (2006) Comparative analysis of substrate and inhibitor interactions with CYP3A4 and CYP3A5. Xenobiotica 36:4, pages 287-299.
Read now
Read now
Articles from other publishers (152)
Kosuke Kinoshita, George Moore & Masahiro Murakami. (2024) Body Weight as a Preferred Method for Normalizing the Computed Tomography-Derived Liver Volume in Dogs without Hepatic Disease. Veterinary Sciences 11:4, pages 153.
Crossref
Crossref
Maxime Le Merdy, Ke Xu Szeto, Jeremy Perrier, Michael B. Bolger & Viera Lukacova. (2024) PBPK Modeling Approach to Predict the Behavior of Drugs Cleared by Metabolism in Pregnant Subjects and Fetuses. Pharmaceutics 16:1, pages 96.
Crossref
Crossref
Guangwei Jia, Congcong Ren, Hongyan Wang & Caixia Fan. (2024) Prediction of drug–drug interactions between roflumilast and CYP3A4/1A2 perpetrators using a physiologically-based pharmacokinetic (PBPK) approach. BMC Pharmacology and Toxicology 25:1.
Crossref
Crossref
Tuomas Tervahauta, Päivi Uutela & Mikko Koskinen. (2023) Metabolism of ropinirole is mediated by several canine CYP enzymes. Veterinary Medicine and Science 9:4, pages 1584-1591.
Crossref
Crossref
Sandra Grañana-Castillo, Angharad Williams, Thao Pham, Saye Khoo, Daryl Hodge, Asangaedem Akpan, Rachel Bearon & Marco Siccardi. (2023) General Framework to Quantitatively Predict Pharmacokinetic Induction Drug–Drug Interactions Using In Vitro Data. Clinical Pharmacokinetics 62:5, pages 737-748.
Crossref
Crossref
Marie-Noëlle Paludetto, Mika Kurkela, Helinä Kahma, Janne T. Backman, Mikko Niemi & Anne M. Filppula. (2023)
Hydroxychloroquine is Metabolized by Cytochrome P450 2D6, 3A4, and 2C8, and Inhibits Cytochrome P450 2D6, while its Metabolites also Inhibit Cytochrome P450 3A
in vitro
. Drug Metabolism and Disposition 51:3, pages 293-305.
Crossref
Crossref
Lien Thi Ngo, Jaeyeon Lee, Hwi-yeol Yun & Jung-woo Chae. (2023) Development of a Physiologically Based Pharmacokinetic Model for Tegoprazan: Application for the Prediction of Drug–Drug Interactions with CYP3A4 Perpetrators. Pharmaceutics 15:1, pages 182.
Crossref
Crossref
CARL DAVIS. 2022. Drug Metabolism Handbook. Drug Metabolism Handbook
527
552
.
Miaoying Shi, Yumeng Dong, Hans Bouwmeester, Ivonne M. C. M. Rietjens & Marije Strikwold. (2022) In vitro–in silico-based prediction of inter-individual and inter-ethnic variations in the dose-dependent cardiotoxicity of R- and S-methadone in humans. Archives of Toxicology 96:8, pages 2361-2380.
Crossref
Crossref
Xiaoqing Chang, Yu-Mei Tan, David G. Allen, Shannon Bell, Paul C. Brown, Lauren Browning, Patricia Ceger, Jeffery Gearhart, Pertti J. Hakkinen, Shruti V. Kabadi, Nicole C. Kleinstreuer, Annie Lumen, Joanna Matheson, Alicia Paini, Heather A. Pangburn, Elijah J. Petersen, Emily N. Reinke, Alexandre J. S. Ribeiro, Nisha Sipes, Lisa M. Sweeney, John F. Wambaugh, Ronald Wange, Barbara A. Wetmore & Moiz Mumtaz. (2022) IVIVE: Facilitating the Use of In Vitro Toxicity Data in Risk Assessment and Decision Making. Toxics 10:5, pages 232.
Crossref
Crossref
Shensheng Zhao, Sebastiaan Wesseling, Ivonne. M. C. M. Rietjens & Marije Strikwold. (2022) Inter-individual variation in chlorpyrifos toxicokinetics characterized by physiologically based kinetic (PBK) and Monte Carlo simulation comparing human liver microsome and Supersome™ cytochromes P450 (CYP)-specific kinetic data as model input. Archives of Toxicology 96:5, pages 1387-1409.
Crossref
Crossref
Josefine Schulz, Antonia Thomas, Ayatallah Saleh, Gerd Mikus, Charlotte Kloft & Robin Michelet. (2022) Towards the Elucidation of the Pharmacokinetics of Voriconazole: A Quantitative Characterization of Its Metabolism. Pharmaceutics 14:3, pages 477.
Crossref
Crossref
Ivani Pauli, Celso de O. Rezende Jr.Brian W. Slafer, Marco A. Dessoy, Mariana L. de Souza, Leonardo L. G. Ferreira, Abraham L. M. Adjanohun, Rafaela S. Ferreira, Luma G. Magalhães, Renata Krogh, Simone Michelan-Duarte, Ricardo Vaz Del Pintor, Fernando B. R. da Silva, Fabio C. Cruz, Luiz C. Dias & Adriano D. Andricopulo. (2022) Multiparameter Optimization of Trypanocidal Cruzain Inhibitors With In Vivo Activity and Favorable Pharmacokinetics. Frontiers in Pharmacology 12.
Crossref
Crossref
Yuching Yang & Xinyuan Zhang. 2022. Systems Medicine. Systems Medicine
57
69
.
Mahadevabharath R. Somayaji, Debarun Das, Harsha Teja Garimella, Carrie L. German, Andrzej J. Przekwas & Laurent Simon. (2021) An integrated biophysical model for predicting the clinical pharmacokinetics of transdermally delivered compounds. European Journal of Pharmaceutical Sciences 167, pages 105924.
Crossref
Crossref
Ryan H. Takahashi, William F. Forrest, Alexander D. Smith, Justine Badee, NaHong Qiu, Stephan Schmidt, Abby C. Collier, Neil Parrott & Stephen Fowler. (2021) Characterization of Hepatic UDP-Glucuronosyltransferase Enzyme Abundance-Activity Correlations and Population Variability Using a Proteomics Approach and Comparison with Cytochrome P450 Enzymes. Drug Metabolism and Disposition 49:9, pages 760-769.
Crossref
Crossref
Micaela B. Reddy, Michael B. Bolger, Grace Fraczkiewicz, Laurence Del Frari, Laibin Luo, Viera Lukacova, Amitava Mitra, Joyce S. Macwan, Jim M. Mullin, Neil Parrott & Aki T. Heikkinen. (2021) PBPK Modeling as a Tool for Predicting and Understanding Intestinal Metabolism of Uridine 5′-Diphospho-glucuronosyltransferase Substrates. Pharmaceutics 13:9, pages 1325.
Crossref
Crossref
Sheila Annie Peters. 2021. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulations
567
577
.
Kefei Wang, Kun Jiang, Xiaoyi Wei, Yulan Li, Tiejie Wang & Yang Song. (2021) Physiologically Based Pharmacokinetic Models Are Effective Support for Pediatric Drug Development. AAPS PharmSciTech 22:6.
Crossref
Crossref
Jieon Lee, Yuching Yang, Xinyuan Zhang, Jianghong Fan, Manuela Grimstein, Hao Zhu & Yaning Wang. (2021) Usage of In Vitro Metabolism Data for Drug‐Drug Interaction in Physiologically Based Pharmacokinetic Analysis Submissions to the US Food and Drug Administration. The Journal of Clinical Pharmacology 61:6, pages 782-788.
Crossref
Crossref
Huiping Huang, Helin Xie, Nupur Chaphekar, Ruichao Xu, Raman Venkataramanan & Xuemei Wu. (2021) A Physiologically Based Pharmacokinetic Analysis To Predict the Pharmacokinetics of Intravenous Isavuconazole in Patients with or without Hepatic Impairment. Antimicrobial Agents and Chemotherapy 65:5.
Crossref
Crossref
John O. Miners, Andrew Rowland, Jonathan J. Novak, Kimberly Lapham & Theunis C. Goosen. (2021) Evidence-based strategies for the characterisation of human drug and chemical glucuronidation in vitro and UDP-glucuronosyltransferase reaction phenotyping. Pharmacology & Therapeutics 218, pages 107689.
Crossref
Crossref
Sara Shum & Nina Isoherranen. (2021) Human Fetal Liver Metabolism of Oxycodone Is Mediated by CYP3A7. The AAPS Journal 23:1.
Crossref
Crossref
Xinning Yang, Jianghong Fan & Lei Zhang. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
595
629
.
Priyanka R. Kulkarni, Amir S. Youssef & Aneesh A. Argikar. 2021. Enzyme Kinetics in Drug Metabolism. Enzyme Kinetics in Drug Metabolism
369
417
.
Santosh Kumar Puttrevu, Sumit Arora, Sebastian Polak & Nikunj Kumar Patel. (2020) Physiologically Based Pharmacokinetic Modeling of Transdermal Selegiline and Its Metabolites for the Evaluation of Disposition Differences between Healthy and Special Populations. Pharmaceutics 12:10, pages 942.
Crossref
Crossref
Sirimas Sudsakorn, Praveen Bahadduri, Jennifer Fretland & Chuang Lu. (2020) 2020 FDA Drug-drug Interaction Guidance: A Comparison Analysis and Action Plan by Pharmaceutical Industrial Scientists. Current Drug Metabolism 21:6, pages 403-426.
Crossref
Crossref
Nyasha Nicole Kapungu, Xueqing Li, Charles Nhachi, Collen Masimirembwa & Roslyn Stella Thelingwani. (2020) In vitro and in vivo human metabolism and pharmacokinetics of S‐ and R‐praziquantel. Pharmacology Research & Perspectives 8:4.
Crossref
Crossref
Gloria Vendrell-Navarro, Holger Scheible, Floriane Lignet, Howard Burt, Christian Luepfert, Andreas Marx, Nada Abla, Piet Swart & Dominique Perrin. (2020) Insights into Praziquantel Metabolism and Potential Enantiomeric Cytochrome P450–Mediated Drug-Drug Interaction. Drug Metabolism and Disposition 48:6, pages 481-490.
Crossref
Crossref
Yong Chen, Meng Ke, Jianwen Xu & Cuihong Lin. (2020) Simulation of the Pharmacokinetics of Oseltamivir and Its Active Metabolite in Normal Populations and Patients with Hepatic Cirrhosis Using Physiologically Based Pharmacokinetic Modeling. AAPS PharmSciTech 21:3.
Crossref
Crossref
Xuemei Wu, Hongfei Zhang, Mohammad Kowser Miah, Steve N. Caritis & Raman Venkataramanan. (2019) Physiologically Based Pharmacokinetic Approach Can Successfully Predict Pharmacokinetics of Citalopram in Different Patient Populations. The Journal of Clinical Pharmacology 60:4, pages 477-488.
Crossref
Crossref
Salil N. Pendse, Alina Efremenko, C. Eric Hack, Marjory Moreau, Pankajini Mallick, Michael Dzierlenga, Chantel I. Nicolas, Miyoung Yoon, Harvey J. Clewell & Patrick D. McMullen. (2020) Population Life-course exposure to health effects model (PLETHEM): An R package for PBPK modeling. Computational Toxicology 13, pages 100115.
Crossref
Crossref
Adrian J. Fretland, Tashinga E. Bapiro, Barry Jones, Roshini Markandu, Alexandra L. Orton & Venkatesh Pilla Reddy. 2020. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters. Identification and Quantification of Drugs, Metabolites, Drug Metabolizing Enzymes, and Transporters
213
236
.
Matthew D. Harwood, Mian Zhang, Shriram M. Pathak & Sibylle Neuhoff. (2019) The Regional-Specific Relative and Absolute Expression of Gut Transporters in Adult Caucasians: A Meta-Analysis. Drug Metabolism and Disposition 47:8, pages 854-864.
Crossref
Crossref
Min Zhang, Xiang You, Meng Ke, Zheng Jiao, Hongwei Wu, Pinfang Huang & Cuihong Lin. (2019) Prediction of Ticagrelor and its Active Metabolite in Liver Cirrhosis Populations Using a Physiologically Based Pharmacokinetic Model Involving Pharmacodynamics. Journal of Pharmaceutical Sciences 108:8, pages 2781-2790.
Crossref
Crossref
Kenichi Umehara, Felix Huth, Yi Jin, Hilmar Schiller, Vassilios Aslanis, Tycho Heimbach & Handan He. (2019) Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions. Drug Metabolism and Personalized Therapy 34:2.
Crossref
Crossref
Todd M. Conner, Ronald C. Reed & Tao Zhang. (2018) A Physiologically Based Pharmacokinetic Model for Optimally Profiling Lamotrigine Disposition and Drug–Drug Interactions. European Journal of Drug Metabolism and Pharmacokinetics 44:3, pages 389-408.
Crossref
Crossref
Go-Wun Choi, Yong-Bok Lee & Hea-Young Cho. (2019) Interpretation of Non-Clinical Data for Prediction of Human Pharmacokinetic Parameters: In Vitro-In Vivo Extrapolation and Allometric Scaling. Pharmaceutics 11:4, pages 168.
Crossref
Crossref
Justine Badée, Stephen Fowler, Saskia N. de Wildt, Abby C. Collier, Stephan Schmidt & Neil Parrott. (2018) The Ontogeny of UDP-glucuronosyltransferase Enzymes, Recommendations for Future Profiling Studies and Application Through Physiologically Based Pharmacokinetic Modelling. Clinical Pharmacokinetics 58:2, pages 189-211.
Crossref
Crossref
Bo Lindmark, Anna Lundahl, Kajsa P Kanebratt, Tommy B Andersson & Emre M Isin. (2018)
Human hepatocytes and cytochrome P450‐selective inhibitors predict variability in human drug exposure more accurately than human recombinant
P450s
. British Journal of Pharmacology 175:11, pages 2116-2129.
Crossref
Crossref
Elaine Tseng, Gwendolyn D. Fate, Gregory S. Walker, Theunis C. Goosen & R. Scott Obach. (2018) Biosynthesis and Identification of Metabolites of Maraviroc and Their Use in Experiments to Delineate the Relative Contributions of Cytochrome P4503A4 versus 3A5. Drug Metabolism and Disposition 46:5, pages 493-502.
Crossref
Crossref
F.P. Guengerich. 2018. Comprehensive Toxicology. Comprehensive Toxicology
54
86
.
Ken-ichi Umehara, Felix Huth, Helen Gu, Hilmar Schiller, Tycho Heimbach & Handan He. (2017) Estimation of fractions metabolized by hepatic CYP enzymes using a concept of inter-system extrapolation factors (ISEFs) – a comparison with the chemical inhibition method. Drug Metabolism and Personalized Therapy 32:4.
Crossref
Crossref
Shriram M. Pathak, Aaron Ruff, Edmund S. Kostewicz, Nikunjkumar Patel, David B. Turner & Masoud Jamei. (2017)
Model-Based Analysis of Biopharmaceutic Experiments To Improve Mechanistic Oral Absorption Modeling: An Integrated
in Vitro in Vivo
Extrapolation Perspective Using Ketoconazole as a Model Drug
. Molecular Pharmaceutics 14:12, pages 4305-4320.
Crossref
Crossref
Hari V. Kalluri, Hongfei Zhang, Steve N. Caritis & Raman Venkataramanan. (2017) A physiologically based pharmacokinetic modelling approach to predict buprenorphine pharmacokinetics following intravenous and sublingual administration. British Journal of Clinical Pharmacology 83:11, pages 2458-2473.
Crossref
Crossref
Rachel H. Rose, David B. Turner, Sibylle Neuhoff & Masoud Jamei. (2017) Incorporation of the Time-Varying Postprandial Increase in Splanchnic Blood Flow into a PBPK Model to Predict the Effect of Food on the Pharmacokinetics of Orally Administered High-Extraction Drugs. The AAPS Journal 19:4, pages 1205-1217.
Crossref
Crossref
Zhou Meng, Sylvain Le Marchand, Deep Agnani, Matthew Szapacs, Harma Ellens & Joe Bentz. (2017) Microvilli Morphology Can Affect Efflux Active P-Glycoprotein in Confluent MDCKII -hMDR1-NKI and Caco-2 Cell Monolayers. Drug Metabolism and Disposition 45:2, pages 145-151.
Crossref
Crossref
Yuji Mukai, Masayuki Narita, Erika Akiyama, Kanami Ohashi, Yasutaka Horiuchi, Yuka Kato, Takaki Toda, Anders Rane & Nobuo Inotsume. (2017) Co-administration of Fluvastatin and CYP3A4 and CYP2C8 Inhibitors May Increase the Exposure to Fluvastatin in Carriers of CYP2C9 Genetic Variants. Biological & Pharmaceutical Bulletin Biological and Pharmaceutical Bulletin 40:7, pages 1078-1085.
Crossref
Crossref
T.H. Grasela, V. Lukacova, D.N. Morris, R.D. Clark, K.A. Andrews & M.B. Bolger. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
51
82
.
L Kuepfer, C Niederalt, T Wendl, J‐F Schlender, S Willmann, J Lippert, M Block, T Eissing & D Teutonico. (2016) Applied Concepts in PBPK Modeling: How to Build a PBPK/PD Model. CPT: Pharmacometrics & Systems Pharmacology 5:10, pages 516-531.
Crossref
Crossref
H. J. Burt, A. E. Riedmaier, M. D. Harwood, H. K. Crewe, K. L. Gill & S. Neuhoff. (2016) Abundance of Hepatic Transporters in Caucasians: A Meta-Analysis. Drug Metabolism and Disposition 44:10, pages 1550-1561.
Crossref
Crossref
Sheila Annie Peters, Christopher R. Jones, Anna-Lena Ungell & Oliver J. D. Hatley. (2016) Predicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical Models. Clinical Pharmacokinetics 55:6, pages 673-696.
Crossref
Crossref
Ruben de Kanter, Patricia N. Sidharta, Stéphane Delahaye, Carmela Gnerre, Jerome Segrestaa, Stephan Buchmann, Christopher Kohl & Alexander Treiber. (2015) Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug–Drug Interactions. Clinical Pharmacokinetics 55:3, pages 369-380.
Crossref
Crossref
X. Yang, K. Atkinson & L. Di. (2015) Novel Cytochrome P450 Reaction Phenotyping for Low-Clearance Compounds Using the Hepatocyte Relay Method. Drug Metabolism and Disposition 44:3, pages 460-465.
Crossref
Crossref
J. Matthew Hutzler & Michael A. Zientek. 2015. New Horizons in Predictive Drug Metabolism and Pharmacokinetics. New Horizons in Predictive Drug Metabolism and Pharmacokinetics
79
130
.
Alexander James, Lars Blumenstein, Ulrike Glaenzel, Yi Jin, Arnold Demailly, Annamaria Jakab, Regine Hansen, Katharine Hazell, Anuradha Mehta, Lucia Trandafir & Piet Swart. (2015) Absorption, distribution, metabolism, and excretion of [14C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemotherapy and Pharmacology 76:4, pages 751-760.
Crossref
Crossref
Alexander V. LyubimovYuan Chen, Jialin Mao & Adrian J. Fretland. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
26
.
Aki T. Heikkinen, Floriane Lignet, Paul Cutler & Neil Parrott. (2015) The role of quantitative ADME proteomics to support construction of physiologically based pharmacokinetic models for use in small molecule drug development. PROTEOMICS – Clinical Applications 9:7-8, pages 732-744.
Crossref
Crossref
Michael A. Zientek & Kuresh Youdim. (2015) Reaction Phenotyping: Advances in the Experimental Strategies Used to Characterize the Contribution of Drug-Metabolizing Enzymes. Drug Metabolism and Disposition 43:1, pages 163-181.
Crossref
Crossref
Hua Bian, Antti Hakkarainen, You Zhou, Nina Lundbom, Vesa M Olkkonen & Hannele Yki‐Järvinen. (2014) Impact of non‐alcoholic fatty liver disease on liver volume in humans. Hepatology Research 45:2, pages 210-219.
Crossref
Crossref
Aki T. Heikkinen, Arno Friedlein, Mariette Matondo, Oliver J. D. Hatley, Aleksanteri Petsalo, Risto Juvonen, Aleksandra Galetin, Amin Rostami-Hodjegan, Ruedi Aebersold, Jens Lamerz, Tom Dunkley, Paul Cutler & Neil Parrott. (2014) Quantitative ADME Proteomics – CYP and UGT Enzymes in the Beagle Dog Liver and Intestine. Pharmaceutical Research 32:1, pages 74-90.
Crossref
Crossref
Barbara A. Wetmore, Brittany Allen, Harvey J. ClewellIIIIII, Timothy Parker, John F. Wambaugh, Lisa M. Almond, Mark A. Sochaski & Russell S. Thomas. (2014) Incorporating Population Variability and Susceptible Subpopulations into Dosimetry for High-Throughput Toxicity Testing. Toxicological Sciences 142:1, pages 210-224.
Crossref
Crossref
Brahim Achour, Jill Barber & Amin Rostami-Hodjegan. (2014) Expression of Hepatic Drug-Metabolizing Cytochrome P450 Enzymes and Their Intercorrelations: A Meta-Analysis. Drug Metabolism and Disposition 42:8, pages 1349-1356.
Crossref
Crossref
Bhagwat Prasad & Jashvant D. Unadkat. (2014) Optimized Approaches for Quantification of Drug Transporters in Tissues and Cells by MRM Proteomics. The AAPS Journal 16:4, pages 634-648.
Crossref
Crossref
Sarah K. Lawrence, Dung Nguyen, Chet Bowen, Lauren Richards-Peterson & Konstantine W. Skordos. (2014) The Metabolic Drug-Drug Interaction Profile of Dabrafenib: In Vitro Investigations and Quantitative Extrapolation of the P450-Mediated DDI Risk. Drug Metabolism and Disposition 42:7, pages 1180-1190.
Crossref
Crossref
Erik Sjögren, Bertil Abrahamsson, Patrick Augustijns, Dieter Becker, Michael B. Bolger, Marcus Brewster, Joachim Brouwers, Talia Flanagan, Matthew Harwood, Christian Heinen, René Holm, Hans-Paul Juretschke, Marlies Kubbinga, Anders Lindahl, Viera Lukacova, Uwe Münster, Sibylle Neuhoff, Mai Anh Nguyen, Achiel van Peer, Christos Reppas, Amin Rostami Hodjegan, Christer Tannergren, Werner Weitschies, Clive Wilson, Patricia Zane, Hans Lennernäs & Peter Langguth. (2014) In vivo methods for drug absorption – Comparative physiologies, model selection, correlations with in vitro methods (IVIVC), and applications for formulation/API/excipient characterization including food effects. European Journal of Pharmaceutical Sciences 57, pages 99-151.
Crossref
Crossref
Heidi J. Einolf & Imad Hanna. 2014. Predictive ADMET. Predictive ADMET
353
396
.
Xiaofeng Li, Tom Suhar, Lateca Glass & Ganesh Rajaraman. 2001. Current Protocols in Pharmacology. Current Protocols in Pharmacology
9.18.1
9.18.10
.
Li Di, Bo Feng, Theunis C. Goosen, Yurong Lai, Stefanus J. Steyn, Manthena V. Varma & R. Scott Obach. (2013) A Perspective on the Prediction of Drug Pharmacokinetics and Disposition in Drug Research and Development. Drug Metabolism and Disposition 41:12, pages 1975-1993.
Crossref
Crossref
Cong Xu, Sara K. Quinney, Yingying Guo, Stephen D. Hall, Lang Li & Zeruesenay Desta. (2013) CYP2B6 Pharmacogenetics–Based In Vitro–In Vivo Extrapolation of Efavirenz Clearance by Physiologically Based Pharmacokinetic Modeling. Drug Metabolism and Disposition 41:12, pages 2004-2011.
Crossref
Crossref
Tonika Bohnert & Lawrence L. Gan. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
61
.
Yuan Lu, Jinbo Yang, Haiyan Zhang & Jin Yang. (2013) Prediction of Warfarin Maintenance Dose in Han Chinese Patients Using a Mechanistic Model Based on Genetic and Non-Genetic Factors. Clinical Pharmacokinetics 52:7, pages 567-581.
Crossref
Crossref
Karen Rowland Yeo, Jane R. Kenny & Amin Rostami-Hodjegan. (2013) Application of in vitro-in vivo extrapolation (IVIVE) and physiologically based pharmacokinetic (PBPK) modelling to investigate the impact of the CYP2C8 polymorphism on rosiglitazone exposure. European Journal of Clinical Pharmacology 69:6, pages 1311-1320.
Crossref
Crossref
Aki T. Heikkinen, Stephen Fowler, Lynn Gray, Jia Li, Ying Peng, Preeti Yadava, Aruna Railkar & Neil Parrott. (2013) In Vitro to in Vivo Extrapolation and Physiologically Based Modeling of Cytochrome P450 Mediated Metabolism in Beagle Dog Gut Wall and Liver. Molecular Pharmaceutics 10:4, pages 1388-1399.
Crossref
Crossref
Marco Siccardi, Adeniyi Olagunju, Kay Seden, Farid Ebrahimjee, Steve Rannard, David Back & Andrew Owen. (2013) Use of a physiologically-based pharmacokinetic model to simulate artemether dose adjustment for overcoming the drug-drug interaction with efavirenz. In Silico Pharmacology 1:1.
Crossref
Crossref
Melanie A. Felmlee, Rutwij A. Dave & Marilyn E. Morris. (2012) Mechanistic Models Describing Active Renal Reabsorption and Secretion: A Simulation-Based Study. The AAPS Journal 15:1, pages 278-287.
Crossref
Crossref
Anne M. Filppula, Mikko Neuvonen, Jouko Laitila, Pertti J. Neuvonen & Janne T. Backman. (2013) Autoinhibition of CYP3A4 Leads to Important Role of CYP2C8 in Imatinib Metabolism: Variability in CYP2C8 Activity May Alter Plasma Concentrations and Response. Drug Metabolism and Disposition 41:1, pages 50-59.
Crossref
Crossref
Sibylle Neuhoff, Lu Gaohua, Howard Burt, Masoud Jamei, Linzhong Li, Geoffrey T. Tucker & Amin Rostami-Hodjegan. 2013. Transporters in Drug Development. Transporters in Drug Development
155
177
.
M. D. Harwood, S. Neuhoff, G. L. Carlson, G. Warhurst & A. Rostami‐Hodjegan. (2012)
Absolute abundance and function of intestinal drug transporters: a prerequisite for fully mechanistic
in vitro–in vivo
extrapolation of oral drug absorption
. Biopharmaceutics & Drug Disposition 34:1, pages 2-28.
Crossref
Crossref
Robert S. Foti, Josh T. Pearson, Simon L. Wong, Julie A. Zalikowski, Michael D. Boudreaux, Samantha P. Prokop, John A. Davis, Christopher Banfield, Maurice G. Emery, Dan A. Rock, Jan L. Wahlstrom, Larry C. Wienkers & Benny M. Amore. (2012) Predicting the Drug Interaction Potential of AMG 853, a Dual Antagonist of the D-Prostanoid and Chemoattractant Receptor-Homologous Molecule Expressed on T Helper 2 Cells Receptors. Drug Metabolism and Disposition 40:12, pages 2239-2249.
Crossref
Crossref
Krishna C. Chimalakonda, Kathryn A. Seely, Stacie M. Bratton, Lisa K. Brents, Cindy L. Moran, Gregory W. Endres, Laura P. James, Paul F. Hollenberg, Paul L. Prather, Anna Radominska-Pandya & Jeffery H. Moran. (2012) Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands. Drug Metabolism and Disposition 40:11, pages 2174-2184.
Crossref
Crossref
M Siccardi, L Almond, A Schipani, C Csajka, C Marzolini, C Wyen, N H Brockmeyer, M Boffito, A Owen & D Back. (2012) Pharmacokinetic and Pharmacodynamic Analysis of Efavirenz Dose Reduction Using an In Vitro–In Vivo Extrapolation Model. Clinical Pharmacology & Therapeutics 92:4, pages 494-502.
Crossref
Crossref
SK Quinney, AN Mohamed, MF Hebert, DM Haas, S Clark, JG Umans, SN Caritis & L Li. (2012) A Semi‐Mechanistic Metabolism Model of CYP3A Substrates in Pregnancy: Predicting Changes in Midazolam and Nifedipine Pharmacokinetics. CPT: Pharmacometrics & Systems Pharmacology 1:9, pages 1-9.
Crossref
Crossref
A Rostami-Hodjegan. (2012) Physiologically Based Pharmacokinetics Joined With In Vitro–In Vivo Extrapolation of ADME: A Marriage Under the Arch of Systems Pharmacology. Clinical Pharmacology & Therapeutics 92:1, pages 50-61.
Crossref
Crossref
Maria Karlgren, Anna Vildhede, Ulf Norinder, Jacek R. Wisniewski, Emi Kimoto, Yurong Lai, Ulf Haglund & Per Artursson. (2012) Classification of Inhibitors of Hepatic Organic Anion Transporting Polypeptides (OATPs): Influence of Protein Expression on Drug–Drug Interactions. Journal of Medicinal Chemistry 55:10, pages 4740-4763.
Crossref
Crossref
Alexander V. LyubimovFrédéric Y. Bois & Masoud Jamei. 2011. Encyclopedia of Drug Metabolism and Interactions. Encyclopedia of Drug Metabolism and Interactions
1
27
.
Nitsupa Wattanachai, Wichittra Tassaneeyakul, Andrew Rowland, David J. Elliot, Kushari Bowalgaha, Kathleen M. Knights & John O. Miners. (2012) Effect of Albumin on Human Liver Microsomal and Recombinant CYP1A2 Activities: Impact on In Vitro-In Vivo Extrapolation of Drug Clearance. Drug Metabolism and Disposition 40:5, pages 982-989.
Crossref
Crossref
Chun Li & Nataraj Kalyanaraman. 2012. ADME‐Enabling Technologies in Drug Design and Development. ADME‐Enabling Technologies in Drug Design and Development
189
212
.
Kenneth Bachmann & Sean Ekins. 2012. Predictive Approaches in Drug Discovery and Development. Predictive Approaches in Drug Discovery and Development
307
329
.
Sheila Annie Peters. 2012. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations. Physiologically‐Based Pharmacokinetic (PBPK) Modeling and Simulations
407
421
.
Xavier Boulenc & Olivier Barberan. (2011) Metabolic-based drug-drug interactions prediction, recent approaches for risk assessment along drug development. dmdi 26:4, pages 147-168.
Crossref
Crossref
Hisakazu Ohtani, Zoe Barter, Tsuyoshi Minematsu, Masatoshi Makuuchi, Yasufumi Sawada & Amin Rostami‐Hodjegan. (2011) Bottom‐up modeling and simulation of tacrolimus clearance: prospective investigation of blood cell distribution, sex and CYP3A5 expression as covariates and assessment of study power. Biopharmaceutics & Drug Disposition 32:9, pages 498-506.
Crossref
Crossref
H. K. Crewe, Z. E. Barter, K. Rowland Yeo & A. Rostami‐Hodjegan. (2011) Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter‐system extrapolation factors. Biopharmaceutics & Drug Disposition 32:6, pages 303-318.
Crossref
Crossref
Nitsupa Wattanachai, Thomas M. Polasek, Tahlia M. Heath, Verawan Uchaipichat, Wongwiwat Tassaneeyakul, Wichittra Tassaneeyakul & John O. Miners. (2011) In vitro–in vivo extrapolation of CYP2C8-catalyzed paclitaxel 6α-hydroxylation: effects of albumin on in vitro kinetic parameters and assessment of interindividual variability in predicted clearance. European Journal of Clinical Pharmacology 67:8, pages 815-824.
Crossref
Crossref
Steven W. Louie & Magang Shou. 2011. Mass Spectrometry in Drug Metabolism and Disposition. Mass Spectrometry in Drug Metabolism and Disposition
83
149
.
Erik Sjögren, Joakim Nyberg, Mats O. Magnusson, Hans Lennernäs, Andrew Hooker & Ulf Bredberg. (2011) Optimal Experimental Design for Assessment of Enzyme Kinetics in a Drug Discovery Screening Environment. Drug Metabolism and Disposition 39:5, pages 858-863.
Crossref
Crossref
Dinko Rekić, Daniel Röshammar, Jackson Mukonzo & Michael Ashton. (2011)
In silico
prediction of efavirenz and rifampicin drug–drug interaction considering weight and CYP2B6 phenotype
. British Journal of Clinical Pharmacology 71:4, pages 536-543.
Crossref
Crossref
Yuan Chen, Liling Liu, Khanh Nguyen & Adrian J. Fretland. (2011) Utility of Intersystem Extrapolation Factors in Early Reaction Phenotyping and the Quantitative Extrapolation of Human Liver Microsomal Intrinsic Clearance Using Recombinant Cytochromes P450. Drug Metabolism and Disposition 39:3, pages 373-382.
Crossref
Crossref
Andrea N. Edginton. (2010) Knowledge‐driven approaches for the guidance of first‐in‐children dosing. Pediatric Anesthesia 21:3, pages 206-213.
Crossref
Crossref
Yi Jin, Markus Zollinger, Hubert Borell, Alfred Zimmerlin & Christopher J. Patten. (2011) CYP4F Enzymes Are Responsible for the Elimination of Fingolimod (FTY720), a Novel Treatment of Relapsing Multiple Sclerosis. Drug Metabolism and Disposition 39:2, pages 191-198.
Crossref
Crossref
Masoud Jamei, Karen R. Yeo, Trevor N. Johnson, Cyrus Ghobadi, Manoranjenni Chetty, Khaled Abduljalil, Gaohua Lu, Farzaneh Salem, Adam Darwich & Amin Rostami-Hodjegan. 2012. Biosimulation in Biomedical Research, Health Care and Drug Development. Biosimulation in Biomedical Research, Health Care and Drug Development
361
386
.
Xavier Boulenc, Wolfgang Schmider & Olivier Barberan. 2011. Drug Discovery and Evaluation: Methods in Clinical Pharmacology. Drug Discovery and Evaluation: Methods in Clinical Pharmacology
133
160
.
J. Matthew Hutzler, Jack Cook & Joseph C. Fleishaker. 2011. Pharmacokinetics in Drug Development. Pharmacokinetics in Drug Development
21
56
.
Frédéric Y. Bois, Masoud Jamei & Harvey J. Clewell. (2010) PBPK modelling of inter-individual variability in the pharmacokinetics of environmental chemicals. Toxicology 278:3, pages 256-267.
Crossref
Crossref
Andrew Parkinson, Brian W. Ogilvie, Brandy L. Paris, Tiffini N. Hensley & Greg J. Loewen. 2010. Biotransformation and Metabolite Elucidation of Xenobiotics. Biotransformation and Metabolite Elucidation of Xenobiotics
1
77
.
Karthik Venkatakrishnan, Michael D. Pickard & Lisa L. von Moltke. (2010) A Quantitative Framework and Strategies for Management and Evaluation of Metabolic Drug-Drug Interactions in Oncology Drug Development. Clinical Pharmacokinetics 49:11, pages 703-727.
Crossref
Crossref
Z. E. Barter, H. F. Perrett, K. Rowland Yeo, D. Allorge, M. S. Lennard & A. Rostami‐Hodjegan. (2010) Determination of a quantitative relationship between hepatic CYP3A5*1/*3 and CYP3A4 expression for use in the prediction of metabolic clearance in virtual populations. Biopharmaceutics & Drug Disposition 31:8-9, pages 516-532.
Crossref
Crossref
M. Teresa Donato, David Hallifax, Laura Picazo, José V. Castell, J. Brian Houston, M. José Gomez-Lechón & Agustin Lahoz. (2010) Metabolite Formation Kinetics and Intrinsic Clearance of Phenacetin, Tolbutamide, Alprazolam, and Midazolam in Adenoviral Cytochrome P450-Transfected HepG2 Cells and Comparison with Hepatocytes and In Vivo. Drug Metabolism and Disposition 38:9, pages 1449-1455.
Crossref
Crossref
R. Scott Obach & Tim F. Ryder. (2010) Metabolism of Ramelteon in Human Liver Microsomes and Correlation with the Effect of Fluvoxamine on Ramelteon Pharmacokinetics. Drug Metabolism and Disposition 38:8, pages 1381-1391.
Crossref
Crossref
Nathalie Perdaems, Helene Blasco, Cedric Vinson, Marylore Chenel, Sarah Whalley, Fanny Cazade & François Bouzom. (2010) Predictions of Metabolic Drug-Drug Interactions Using Physiologically Based Modelling. Clinical Pharmacokinetics 49:4, pages 239-258.
Crossref
Crossref
Carl D. Davis & A. David Rodrigues. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
58
.
Jane R. Kenny, Dermot F. McGinnity, Ken Grime & Robert J. Riley. 2010. Pharmaceutical Sciences Encyclopedia. Pharmaceutical Sciences Encyclopedia
1
38
.
Trevor N. Johnson, Koen Boussery, Karen Rowland-Yeo, Geoffrey T. Tucker & Amin Rostami-Hodjegan. (2010) A Semi-Mechanistic Model to Predict the Effects of Liver Cirrhosis on Drug Clearance. Clinical Pharmacokinetics 49:3, pages 189-206.
Crossref
Crossref
Beth Miskimins Mills, Matthew J. Zaya, Rodney R. Walters, Kenneth L. Feenstra, Julie A. White, Jason Gagne & Charles W. Locuson. (2010) Current Cytochrome P450 Phenotyping Methods Applied to Metabolic Drug-Drug Interaction Prediction in Dogs. Drug Metabolism and Disposition 38:3, pages 396-404.
Crossref
Crossref
M. T. BARATTA, M. J. ZAYA, J. A. WHITE & C. W. LOCUSON. (2010) Canine CYP2B11 metabolizes and is inhibited by anesthetic agents often co-administered in dogs. Journal of Veterinary Pharmacology and Therapeutics 33:1, pages 50-55.
Crossref
Crossref
F.P. Guengerich. 2010. Comprehensive Toxicology. Comprehensive Toxicology
41
76
.
Tonika Bohnert & Liang‐Shang Gan. 2009. Enzyme Inhibition in Drug Discovery and Development. Enzyme Inhibition in Drug Discovery and Development
91
176
.
Marcel J. de Groot, Florian Wakenhut, Gavin Whitlock & Ruth Hyland. (2009) Understanding CYP2D6 interactions. Drug Discovery Today 14:19-20, pages 964-972.
Crossref
Crossref
Ruth Hyland, R. Scott Obach, Chad Stoner, Michael West, Michael R. Wester, Kuresh Youdim & Michael Zientek. 2009. Hit and Lead Profiling. Hit and Lead Profiling
165
196
.
Masato Chiba, Yasuyuki Ishii & Yuichi Sugiyama. (2009) Prediction of Hepatic Clearance in Human From In Vitro Data for Successful Drug Development. The AAPS Journal 11:2.
Crossref
Crossref
Rowan A. Stringer, Claire Strain-Damerell, Paul Nicklin & J. Brian Houston. (2009) Evaluation of Recombinant Cytochrome P450 Enzymes as an in Vitro System for Metabolic Clearance Predictions. Drug Metabolism and Disposition 37:5, pages 1025-1034.
Crossref
Crossref
Makiko Kusama, Kazuya Maeda, Koji Chiba, Akinori Aoyama & Yuichi Sugiyama. (2008) Prediction of the Effects of Genetic Polymorphism on the Pharmacokinetics of CYP2C9 Substrates from In Vitro Data. Pharmaceutical Research 26:4, pages 822-835.
Crossref
Crossref
Charles W. Locuson, Brian T. Ethell, Michael Voice, David Lee & Kenneth L. Feenstra. (2009)
Evaluation of
Escherichia coli
Membrane Preparations of Canine CYP1A1, 2B11, 2C21, 2C41, 2D15, 3A12, and 3A26 with Coexpressed Canine Cytochrome P450 Reductase
. Drug Metabolism and Disposition 37:3, pages 457-461.
Crossref
Crossref
Carl D. Davis & A. David Rodrigues. 2009. Drug Metabolism Handbook. Drug Metabolism Handbook
391
447
.
Linh M. Van, Sunil Sarda, Judith A. Hargreaves & Amin Rostami‐Hodjegan. (2009) Metabolism of Dextrorphan by CYP2D6 in Different Recombinantly Expressed Systems and its Implications for the In Vitro Assessment of Dextromethorphan Metabolism. Journal of Pharmaceutical Sciences 98:2, pages 763-771.
Crossref
Crossref
Simbarashe Peter Zvada, Tangai Edwin Chagwedera, Rosemary Chigwanda & Collen Mutowembwa Masimirembwa. (2009) An Experimental Pharmacokinetic Computer Program to Predict Potential Drug-Drug Interactions. The Open Drug Metabolism Journal 3, pages 8-16.
Crossref
Crossref
Masoud Jamei, Gemma L. Dickinson & Amin Rostami-Hodjegan. (2009) A Framework for Assessing Inter-individual Variability in Pharmacokinetics Using Virtual Human Populations and Integrating General Knowledge of Physical Chemistry, Biology, Anatomy, Physiology and Genetics: A Tale of ‘Bottom-Up’ vs ‘Top-Down’ Recognition of Covariates. Drug Metabolism and Pharmacokinetics 24:1, pages 53-75.
Crossref
Crossref
Hege Christensen, Liv Mathiesen, Lillian W. Postvoll, Bjørn Winther & Espen Molden. (2009) Different Enzyme Kinetics of Midazolam in Recombinant CYP3A4 Microsomes from Human and Insect Sources. Drug Metabolism and Pharmacokinetics 24:3, pages 261-268.
Crossref
Crossref
Kazunobu Aoyama, Kouichi Yoshinari, Hye-Ji Kim, Kiyoshi Nagata & Yasushi Yamazoe. (2009) Simultaneous Expression of Plural Forms of Human Cytochrome P450 at Desired Ratios in HepG2 Cells: Adenovirus-mediated Tool for Cytochrome P450 Reconstitution. Drug Metabolism and Pharmacokinetics 24:3, pages 209-217.
Crossref
Crossref
Barry C. Jones, Donald S. Middleton & Kuresh Youdim. 2009. Progress in Medicinal Chemistry Volume 47. Progress in Medicinal Chemistry Volume 47
239
263
.
J. M. Ritter. (2008) Prediction and Reverse Prediction in Therapeutics and Toxicology. British Journal of Clinical Pharmacology 66:4, pages 427-429.
Crossref
Crossref
Ruth Hyland, Maurice Dickins, Claire Collins, Hannah Jones & Barry Jones. (2008)
Maraviroc:
in vitro
assessment of drug–drug interaction potential
. British Journal of Clinical Pharmacology 66:4, pages 498-507.
Crossref
Crossref
Andrew Rowland, David J. Elliot, Kathleen M. Knights, Peter I. Mackenzie & John O. Miners. (2008) The “Albumin Effect” and in Vitro-in Vivo Extrapolation: Sequestration of Long-Chain Unsaturated Fatty Acids Enhances Phenytoin Hydroxylation by Human Liver Microsomal and Recombinant Cytochrome P450 2C9. Drug Metabolism and Disposition 36:5, pages 870-877.
Crossref
Crossref
Kuresh A. Youdim, Aref Zayed, Maurice Dickins, Alex Phipps, Michelle Griffiths, Amanda Darekar, Ruth Hyland, Odette Fahmi, Susan Hurst, David R. Plowchalk, Jack Cook, Feng Guo & R. Scott Obach. (2008)
Application of CYP3A4
in vitro
data to predict clinical drug–drug interactions; predictions of compounds as objects of interaction
. British Journal of Clinical Pharmacology 65:5, pages 680-692.
Crossref
Crossref
John C. Lipscomb & Torka S. Poet. (2008) In vitro measurements of metabolism for application in pharmacokinetic modeling. Pharmacology & Therapeutics 118:1, pages 82-103.
Crossref
Crossref
Timothy W. Harper & Patrick J. Brassil. (2008) Reaction Phenotyping: Current Industry Efforts to Identify Enzymes Responsible for Metabolizing Drug Candidates. The AAPS Journal 10:1, pages 200-207.
Crossref
Crossref
Dan Rock, Jan Wahlstrom & Larry Wienkers. 2008. Antitargets. Antitargets
195
246
.
Gemma L. Dickinson & Amin Rostami‐Hodjegan. 2007. Biosimulation in Drug Development. Biosimulation in Drug Development
425
446
.
H. F. Perrett, Z. E. Barter, B. C. Jones, H. Yamazaki, G. T. Tucker & A. Rostami-Hodjegan. (2007) Disparity in Holoprotein/Apoprotein Ratios of Different Standards Used for Immunoquantification of Hepatic Cytochrome P450 Enzymes. Drug Metabolism and Disposition 35:10, pages 1733-1736.
Crossref
Crossref
Linh M. Van, Judith. A. Hargreaves, Martin S. Lennard, Geoffrey T. Tucker & Amin Rostami-Hodjegan. (2007) Inactivation of CYP2D6 by methylenedioxymethamphetamine in different recombinant expression systems. European Journal of Pharmaceutical Sciences 32:1, pages 8-16.
Crossref
Crossref
Gemma L. Dickinson, Martin S. Lennard, Geoffrey T. Tucker & Amin Rostami‐Hodjegan. (2007)
The use of mechanistic DM‐PK‐PD modelling to assess the power of pharmacogenetic studies –
CYP2C9
and warfarin as an example
. British Journal of Clinical Pharmacology 64:1, pages 14-26.
Crossref
Crossref
Andrew Rowland, Paraskevi Gaganis, David J. Elliot, Peter I. Mackenzie, Kathleen M. Knights & John O. Miners. (2007) Binding of Inhibitory Fatty Acids Is Responsible for the Enhancement of UDP-Glucuronosyltransferase 2B7 Activity by Albumin: Implications for in Vitro-in Vivo Extrapolation. Journal of Pharmacology and Experimental Therapeutics 321:1, pages 137-147.
Crossref
Crossref
Gemma L. Dickinson, Saeed Rezaee, Nicholas J. Proctor, Martin S. Lennard, Geoffrey T. Tucker & Amin Rostami‐Hodjegan. (2013) Incorporating In Vitro Information on Drug Metabolism Into Clinical Trial Simulations to Assess the Effect of CYP2D6 Polymorphism on Pharmacokinetics and Pharmacodynamics: Dextromethorphan as a Model Application. The Journal of Clinical Pharmacology 47:2, pages 175-186.
Crossref
Crossref
Amin Rostami-Hodjegan & Geoffrey T. Tucker. (2007) Simulation and prediction of in vivo drug metabolism in human populations from in vitro data. Nature Reviews Drug Discovery 6:2, pages 140-148.
Crossref
Crossref
M. Dickins, A. Galetin & N. Proctor. 2007. Comprehensive Medicinal Chemistry II. Comprehensive Medicinal Chemistry II
827
846
.
Trevor N. Johnson, Geoffrey T. Tucker, M. Stuart Tanner & Amin Rostami-Hodjegan. (2005) Changes in liver volume from birth to adulthood: A meta-analysis. Liver Transplantation 11:12, pages 1481-1493.
Crossref
Crossref
Lauri I. Kajosaari, Jouko Laitila, Pertti J. Neuvonen & Janne T. Backman. (2005)
Metabolism of Repaglinide by CYP2C8 and CYP3A4
in vitro
: Effect of Fibrates and Rifampicin
. Basic & Clinical Pharmacology & Toxicology 97:4, pages 249-256.
Crossref
Crossref
Sandra Coecke, Bas J. Blaauboer, Greetje Elaut, Stuart Freeman, Andreas Freidig, Nigel Gensmantel, Peter Hoet, Vassilios M. Kapoulas, Bernhard Ladstetter, Gill Langley, David Leahy, Geert Mannens, Annarita Meneguz, Mario Monshouwer, Ben Nemery, Olavi Pelkonen, Walter Pfaller, Pilar Prieto, Nick Proctor, Vera Rogiers, Amin Rostami-Hodjegan, Enrico Sabbioni, Winfried Steiling & Johannes J.M. van de Sandt. (2019) 3.9. Toxicokinetics and Metabolism. Alternatives to Laboratory Animals 33:1_suppl, pages 147-175.
Crossref
Crossref
Kenneth Bachmann, Urvi Telang, James Byers & Wayne Hoss. (2005) The Processing of the Selective M1 Agonist CDD-0102-J by Human Hepatic Drug Metabolizing Enzymes. American Journal of Therapeutics 12:4, pages 300-305.
Crossref
Crossref
Kenneth A Bachmann & Jeffrey D Lewis. (2017) Predicting Inhibitory Drug—Drug Interactions and Evaluating Drug Interaction Reports Using Inhibition Constants. Annals of Pharmacotherapy 39:6, pages 1064-1072.
Crossref
Crossref
Aleksandra Galetin, Caroline Brown, David Hallifax, Kiyomi Ito & J. Brian Houston. (2004) UTILITY OF RECOMBINANT ENZYME KINETICS IN PREDICTION OF HUMAN CLEARANCE: IMPACT OF VARIABILITY, CYP3A5, AND CYP2C19 ON CYP3A4 PROBE SUBSTRATES. Drug Metabolism and Disposition 32:12, pages 1411-1420.
Crossref
Crossref
Pawel BaranczewskiAndreas KallinAnna AnderssonShadi HagigiMaria ÅbergHans PostlindLouise Mankowitz. (2004) Development of an Assay Using 4-Trifluoromethylumbelliferyl as a Marker Substrate for Assessment of Drug–Drug Interactions to Multiple Isoforms of UDP-Glucuronosyltransferases. ASSAY and Drug Development Technologies 2:4, pages 345-352.
Crossref
Crossref